Capital Group Investment Management’s Royalty Pharma RPRX Stock Holding History

Capital Group Investment Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.07M	Buy	126,078 +2,054	+2%	+$107K	1.07%	27
2026 Q1	$5.95M	Buy	124,024 +58,511	+89%	+$2.56M	1.02%	25
2025 Q4	$2.53M	Buy	65,513 +20,168	+44%	+$769K	0.41%	62
2025 Q3	$1.6M	Hold	45,345	–	–	0.27%	87
2025 Q2	$1.63M	Buy	+45,345	New	+$1.5M	0.29%	85

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital Group Investment Management's RPRX Position: Q2 2026 in Review

Capital Group Investment Management increased its Royalty Pharma (RPRX) stake by 1.7% in Q2 2026, buying an estimated $107K and bringing the position to 126,078 shares worth $7.07M. The position accounts for 1.07% of the portfolio, ranked #27.

Capital Group Investment Management first reported a position in RPRX in Q2 2025 and has held it in 5 quarters since. 646 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Capital Group Investment Management held 126,078 shares of Royalty Pharma worth $7.07M as of Q2 2026.
Capital Group Investment Management bought 2,054 Royalty Pharma shares in Q2 2026, an estimated $107K.
Royalty Pharma made up 1.07% of Capital Group Investment Management's portfolio in Q2 2026, its #27 holding.
Capital Group Investment Management first reported a position in Royalty Pharma in Q2 2025 and has held it in 5 quarters since.
646 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Capital Group Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.